Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: the 2010 GLADAOF Lecture

Página do item simplificado
dc.contributor.authorFernando Arevalo, J.
dc.contributor.authorSanchez, Juan G.
dc.contributor.authorLasave, Andres F.
dc.contributor.authorWu, Lihteh
dc.contributor.authorMaia, Mauricio [UNIFESP]
dc.contributor.authorBonafonte, Sergio
dc.contributor.authorBrito, Miguel
dc.contributor.authorAlezzandrini, Arturo A.
dc.contributor.authorRestrepo, Natalia
dc.contributor.authorBerrocal, Maria H.
dc.contributor.authorSaravia, Mario
dc.contributor.authorFarah, Michel Eid [UNIFESP]
dc.contributor.authorFromow-Guerra, Jans
dc.contributor.authorMorales-Canton, Virgilio
dc.contributor.institutionCaracas Clin Opthalmol Ctr
dc.contributor.institutionINIO
dc.contributor.institutionInst Cirugia Ocular
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionCtr Oftalmol Bonafonte
dc.contributor.institutionIDEO
dc.contributor.institutionUniv Buenos Aires
dc.contributor.institutionUniv Puerto Rico
dc.contributor.institutionHosp Univ Austral
dc.contributor.institutionAsociac Evitar Ceguera Mexico 04030
dc.date.accessioned2016-01-24T14:05:52Z
dc.date.available2016-01-24T14:05:52Z
dc.date.issued2011-01-01
dc.description.abstractThis paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter interventional comparative case series of intravitreal injections of 1.25 or 2.5 mg of bevacizumab for DME, PDR without tractional retinal detachment (TRD), and patients who experienced the development or progression of TRD after an intravitreal injection of 1.25 or 2.5 mg of bevacizumab before vitrectomy for the management of PDR. the results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse DME. Therefore, in the future this new therapy could complement focal/grid laser photocoagulation in DME. in PDR, this new option could be an adjuvant agent to panretina photocoagulation so that more selective therapy may be applied. Finally, TRD in PDR may occur or progress after IVB used as an adjuvant to vitrectomy. Surgery should be performed 4 days after IVB. Most patients had poorly controlled diabetes mellitus associated with elevated HbA1c, insulin administration, PDR refractory to panretinal photocoagulation, and longer time between IVB and vitrectomy.en
dc.description.affiliationCaracas Clin Opthalmol Ctr, Retina & Vitreous Serv, Caracas 1010, Venezuela
dc.description.affiliationINIO, Retina & Vitreous Serv, Medellin, Colombia
dc.description.affiliationInst Cirugia Ocular, Retina & Vitreous Serv, San Jose, Costa Rica
dc.description.affiliationUniversidade Federal de São Paulo, Inst Visao, Dept Oftalmol, BR-04021001 São Paulo, Brazil
dc.description.affiliationCtr Oftalmol Bonafonte, Retina & Vitreous Serv, Barcelona, Spain
dc.description.affiliationIDEO, Retina & Vitreous Serv, Maracaibo, Venezuela
dc.description.affiliationUniv Buenos Aires, Fac Med, OFTALMOS, Buenos Aires, DF, Argentina
dc.description.affiliationUniv Puerto Rico, Dept Ophthalmol, San Juan, PR 00936 USA
dc.description.affiliationHosp Univ Austral, Dept Ophthalmol, Buenos Aires, DF, Argentina
dc.description.affiliationAsociac Evitar Ceguera Mexico 04030, Hosp Dr Luis Sanchez Bulnes, Mexico City, DF, Mexico
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Inst Visao, Dept Oftalmol, BR-04021001 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipArevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela
dc.format.extent13
dc.identifierhttp://dx.doi.org/10.1155/2011/584238
dc.identifier.citationJournal of Ophthalmology. New York: Hindawi Publishing Corporation, 13 p., 2011.
dc.identifier.doi10.1155/2011/584238
dc.identifier.fileWOS000306790100022.pdf
dc.identifier.issn2090-004X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/33206
dc.identifier.wosWOS:000306790100022
dc.language.isoeng
dc.publisherHindawi Publishing Corporation
dc.relation.ispartofJournal of Ophthalmology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleIntravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: the 2010 GLADAOF Lectureen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000306790100022.pdf
Tamanho:
4.61 MB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Outras produções